LuminoMark inj. 0.2mL

DRUG2 trials

Sponsors

Hanlim Pharm. Co., Ltd., Seoul St. Mary's Hospital

Conditions

Breast DiseasesColorectal CancerEndoscopic Tattoo of Suspected Colon CancerIndocyanine Green (ICG)

Phase 2

To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions

CompletedNCT03743259

Hanlim Pharm. Co., Ltd.Breast Diseases

Start: 2018-05-29End: 2019-04-22Updated: 2019-06-06

Unknown Phase

Confirming the Accuracy of Endoscopic Marking Using a New Marker, a Novel Luminomarker, in Lesion Marking Before Colorectal Cancer Surgery.

Enrolling by invitationNCT07380867

Seoul St. Mary's HospitalColorectal Cancer, Endoscopic Tattoo of Suspected Colon Cancer, Indocyanine Green (ICG)

Start: 2025-12-22End: 2026-12-31Target: 30Updated: 2026-02-02

Related Papers

The efficacy and safety of indocyanine green-hyaluronic acid mixture (LuminoMark™) for localization in patients with non-palpable breast lesions: a multi-center open-label parallel phase-2 clinical trial

BMC Surgery2021-03-168 citations